Overview
PBD Biotech develops Actiphage®, a patented phage-based diagnostic technology that detects live mycobacteria, the cause of tuberculosis, in blood samples and other specimens within 8 hours. The test distinguishes viable from non-viable organisms, enabling differentiation between active infections and vaccination responses. Recent innovations include a lyophilized PCR reaction bead for ambient shipping of active TB tests.
Frequently asked questions
- What is Actiphage® and how does it work?
- Actiphage® is PBD Biotech's proprietary phage-based technology that detects extremely low levels of live mycobacteria in blood and other samples from various species, providing results in 8 hours by distinguishing viable organisms from non-viable ones.
- What samples can be used with PBD Biotech's tests?
- The tests work with blood samples primarily for TB screening, and research explores tongue swabs and other biosamples, with studies on timing constraints post-sampling.
- What shipping and storage solutions support PBD Biotech products?
- A new lyophilized PCR reaction bead enables ambient shipping without cold chain requirements, and partnerships like Cryoniss provide safe storage and distribution for TB screening products.